EGFR and non-small cell lung carcinoma: Despite the higher frequency of EGFR mutations and other pathogenic and targetable mutations in Latin American NSCLC patients, the access to molecular assays and target therapies remain a limitation,20 especially in countries like Peru where there is a great fragmentation of its health system.17